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Lithium limits trimethyltin-induced cytotoxicity
and proinflammatory response in microglia
without affecting the concurrent autophagy
impairment
Q1 Cinzia Fabrizia, Elena Pompilia*, Francesca Sommaa, Stefania De Vitoa,
Viviana Ciracia, Marco Articob, Paola Lenzic, Francesco Fornaic,d
and Lorenzo Fumagallia
ABSTRACT: Trimethyltin (TMT) is a highly toxic molecule present as an environmental contaminant causing neurodegeneration
particularly of the limbic system both in humans and in rodents. We recently described the occurrence of impairment in the late
stages of autophagy in TMT-intoxicated astrocytes. Here we show that similarly to astrocytes also in microglia, TMT induces the
precocious block of autophagy indicated by the accumulation of the autophagosome marker, microtubule associated protein
light chain 3. Consistent with autophagy impairment we observe in TMT-treated microglia the accumulation of p62/SQSTM1, a
protein specifically degraded through this pathway. Lithium has been proved effective in limiting neurodegenerations and, in
particular, in ameliorating symptoms of TMT intoxication in rodents. In our in vitro model, lithium displays a pro-survival and
anti-inflammatory action reducing both cell death and the proinflammatory response of TMT-treated microglia. In particular,
lithium exerts these activities without reducing TMT-induced accumulation of light chain 3 protein. In fact, the autophagic block
imposed by TMT is unaffected by lithium administration. These results are of interest as defects in the execution of autophagy are
frequently observed in neurodegenerative diseases and lithium is considered a promising therapeutic agent for these patholo-
gies. Thus, it is relevant that this cation can still maintain its pro-survival and anti-inflammatory role in conditions of autophagy
block. Copyright © 2016 John Wiley & Sons, Ltd.
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Introduction
Trimethyltin (TMT) is a highly neurotoxic molecule belonging to
the family of organotins. These compounds during the last
decades have been used for a variety of industrial and agricultural
applications as pesticides, fungicides and antifouling paints for
ship hulls (Appel, 2004). Some of them have been banned such
as tributyltin chloride in the United States during the 1980s (Fent,
1996) but despite their toxicity methyltins are still heavily used as
heat stabilizers in polyvinyl chloride production (Dobson et al.,
2005). Leaching of organotins from polyvinyl chloride material
has been proposed as one of the principal sources of environmen-
tal contamination (Richardson & Edwards, 2009) and in fact, they
can be detected as contaminants in fresh water, tap water, seawa-
ter, algae and fish (Borghi & Porte, 2002; Fent, 1996; Mundy &
Freudenrich, 2006). Although methyltin is more widely used,
dimethyltin is characterized by low direct toxicity and its conver-
sion into TMT by the addition of amethyl group has been reported
to occur in vivoQ2 (Furuhashi et al., 2008).
TMT damages specific populations of neurons and in particular
the limbic system, including the pyriform/enthorinal cortex, olfac-
tory bulb, amygdala and hippocampal formation (Chang & Dyer,
1985; Kawada et al., 2008). Themain symptoms of TMT intoxication
include aggressive behavior, disorientation, seizures and severe
memory loss (Kreyberg et al., 1992; Reuhl & Cranmer, 1984).
Similarly to other neurodegenerative disorders, TMT-induced
neurodegeneration is characterized by neuronal selectivity and
neuroinflammation is always accompanied by both astroglial and
microglial activation Q3(Geloso et al., 2011; Pompili et al., 2004,
2011). In the hippocampus of TMT-intoxicated rodents, microglia
activation is observed during the first post-intoxication day and
then persists over a long period (Koczyk & Oderfeld-Nowak,
2000). At the same time in the hippocampus, proinflammatory
cytokines are upregulated (Bruccoleri & Harry, 2000). TMT adminis-
tered in vitro to microglial cultures determines the increase in the
expression of M1 markers (tumor necrosis factor [TNF]-α, inter-
leukin [IL]-1β, IL-6 and inducible nitric oxide synthase) and the de-
crease of the M2markers (CD206 and arginase-1) (Kim et al., 2014).
Recently, TMT was demonstrated to activate directly the BV-2
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microglial cell line via the NADPH oxidase-dependent reactive
oxygen species generation (Kim & Kim, 2015).
A general response of cells exposed to stressful conditions is the
activation of autophagy. This evolutionary conserved catabolic
pathway aims to remove damaged organelles and misfolded
proteins and generally displays a cytoprotective function
(Nikoletopoulou et al., 2013). It is initiated by the formation of a
double-membrane vesicle known as an autophagosome, which
engulfs aggregated proteins or entire organelles. After fusion with
lysosomes, the cargo is finally degraded (for a recent review see
Klionsky et al., 2016). Our previous data showed the importance
of the autophagic pathway in improving the survival of neuronal
cells exposed to TMT (Fabrizi et al., 2012, 2014). Moreover, we re-
cently reported that in astrocytes, TMT determines the impairment
of the late stages of autophagy limiting autophagosome move-
ment and thus their maturation into autophagolysosomes (Fabrizi
et al., 2016).
In this paper, we wanted to answer the question as to whether
the TMT-induced impairment of autophagy was restricted to as-
trocytes or instead could be a possible common feature of the
reaction of glial cells to this toxic compound. Thus, we extended
our previous observations to microglia, which are considered the
resident macrophages of the central nervous system. During neu-
rodegenerative diseases, microglial cells become activated and
can produce highly toxic molecules such as radical species leading
to further neuronal dysfunction and neurodegeneration.
Moreover, as lithium neuroprotective activity has been proved
in many different experimental settings, including TMT intoxica-
tion (Kim et al., 2013; Yoneyama et al., 2014), we studied if lithium
could limit microglial response to TMT in our culture model
system. Interestingly, lithium has been shown to modulate the
autophagic pathway functioning both as an inducer of autophagy
at low concentrations (0.5mM) and as an inhibitor of the same
pathway when used at concentrations higher than 2mM (Sarkar
& Rubinsztein, 2006; Sarkar et al., 2008). Owing to its multiple
molecular targets, the lithium mechanism of action is still elusive
(for a review, see Chiu et al., 2013).
Materials and methods
Cell cultures and treatments
All procedures were carried out in accordancewith Italian laws and
guidelines established for the care and use of animals in research.
Microglial cells were prepared from the cortex of newborn (P4)
Sprague–Dawley rats, as described previously (Pompili et al.,
2011). Briefly, after 14 days in culture, microglial cells were se-
parated from the underlying astrocytic monolayer by gentle agita-
tion and cells were cultured in Dulbecco minimal Eagle’s medium
(Invitrogen, ItalyQ4 ) supplemented with 10% fetal calf serum (Sigma,
Milan, Italy) in 5% CO2. Cultures routinely consisted of ≥95%
microglial cells as determined by staining with Griffonia
simplicifolia isolectin B4 (Sigma, St. Louis, MO, USA).
Microglial cells (1× 105 cells cm2) were seeded on to 96-, 24- or
six-well plates depending on the experiment. After 24 h from
seeding cells were treated with TMT (10μM; Heraeus, Karlsrube,
Germany), lithium chloride (0.5, 1, 2mM), 0.5μM rapamycin, 10μM
indirubin-3′-monoxime, 20nM SB-216763, 100 nM bafilomycin A1
and 10mM 3-methyladenine. All these compounds were used
alone or in combination for different times ranging from 3 to
48h as reported in the figure legends. All reagents were from
Sigma-AldrichQ5 unless otherwise stated.
Assessment of cell viability
Cell death was evaluated bymeasuring the release of lactate dehy-
drogenase in culture medium by the Cytotoxicity Detection Kit
(Roche, Mannheim, Germany) according to the manufacturer’s
protocols.
Terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling
The DNA fragmentation of apoptotic cells was detected using the
terminal deoxynucleotidyl transferase-mediated biotinylated UTP
nick end labeling (TUNEL) kit (In Situ Cell Death Detection Kit;
Roche). Cells were cultured on coverslips and at the end of the
drug treatment fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer pH7.4 (PBS) at room temperature for 15min and then incu-
batedwith a permeabilizing solution (0.1% Triton X-100) for 10min
at 4 °C. The cells were then incubated with the TUNEL reaction
mixture for 60min at 37 °C and visualized by inverted fluorescence
microscopy (Eclipse E600; Nikon Instruments SpA, Firenze, Italy Q6).
TUNEL-positive nuclei were counted in 10 non-overlapping fields
per coverslip and then converted to percentage by comparing
TUNEL-positive counts with the total cell nuclei visualized by
4′,6′-diamino-2-phenylindole counterstaining.
Monodansylcadaverine
Living cells plated on coverslips were incubated with 0.05mM
monodansylcadaverine (MDC; Sigma Q7) (Biederbick et al., 1995) in
PBS at 37 °C for 10min. Cells were washed three times in PBS
and then immediately analyzed by fluorescence microscopy.
Western blotting
Treated and untreated cells were lysed in RIPA buffer containing
protease and phosphatase inhibitors (Protease Inhibitor Cocktail
and Phosphatase Inhibitor Cocktail 2; Sigma Q8). To detect both solu-
ble and insoluble aggregates of p62/SQSTM1, cells were lysed di-
rectly in 100μl 2 × sodium dodecyl sulfate (SDS)–polyacrylamide
gel electrophoresis gel loading buffer (125mM Tris–HCl, pH7.4,
4% SDS, 0.04% bromophenol blue, 30mgml1 DTT added imme-
diately before use), sonicated three times for 5 s and then boiled
for 5min (Bjørkøy et al., 2009). All samples were clarified by centri-
fugation at 1000 rpm for 5min Q9. Equivalent amount of protein
(10μg) from each sample was electrophoretically resolved on
12.5% precast SDS-polyacrylamide gels (ExcelGel; GE Healthcare
Biosciences Q10) using horizontal apparatus (Pharmacia Biotech, Upp-
sala, Sweden). Then, separated proteins were electro-transferred
on to nitrocellulose membranes (Schleicher & Schuell Q11) by a semi-
dry system (Novablot; Pharmacia Biotech). Membranes were
blocked with 3% non-fat milk in PBS and then incubated (over-
night at 4 °C) with the following antibodies: anti-light chain (LC)
3B (Sigma Q12; 1: 1000 in 3% bovine serum albumin in PBS), anti-
p62/SQSTM1 (MBL, PM045; 1: 1000 in 3% non-fat milk in PBS). After
extensive washing with PBS containing 0.1% Tween-20, blots
were incubated with 1: 2000 dilution of horseradish peroxidase-
conjugated secondary antibody (Amersham Biosciences Q13) for 1 h
at room temperature. Immunopositive bands were detected
with a chemiluminescence detection system (GEHealthcare Biosci-
ences). To check for equal loading of the gel, membranes were
stripped and reprobed with mouse anti-β-actin or anti-GAPDH
Fabrizi C. et al.
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antibodies (1: 20 000; SigmaQ14 ). Densitometric analysis was per-
formed with the Quantity One software (Bio-Rad LaboratoriesQ15 ).
Enzyme-linked immunosorbent assay
The release of TNF-α and IL-10 into culture supernatants was de-
termined by standard enzyme-linked immunosorbent assay
techniques according to the manufacturer’s instructions (R&D
Systems, MN, USAQ16 ).
Animals and immunohistochemistry
Male Sprague–Dawley rats (7weeks old, weighing 250g) (Charles
River, Italy) were housed in a temperature- and humidity-
controlled room (21±5 °C and 60% humidity) and fed ad libitum
with standard laboratory diet and water. All procedures were
carried out in accordance with Italian laws and guidelines
established for the care and the use of animals in research. Rats
received a single intraperitoneal dose of TMT (8mgkg1 body
weight; Heraeus) or vehicle (saline) and were killed at 7 days after
treatment. Brains were rapidly removed, embedded in OCT com-
pound (Killik; Bio-Optica, ItalyQ17 ), and frozen on methylbutane
precooled with liquid nitrogen as previously reported (Pompili
et al., 2011).
Sagittal cryostatic sections (7μm thickness) from saline and
TMT-treated rats were fixed with 4% paraformaldehyde in PBS
(pH7.4) at room temperature for 10min. After quenching auto-
fluorescence with 0.05M ammonium chloride and saturation of
non-specific sites with 3% normal donkey serum (BioCell Research
Laboratories, Rancho Dominguez, CA, USA) and 0.1% Triton X-100,
sections were incubated overnight at 4 °C with rabbit anti-p62/
SQSTM1 (1: 500; MBL, PM045) and mouse anti-OX42 (1: 100;
Serotec, Oxford, UK). After washing, the sections were incubated
with a mixture of donkey Dy-light 549 antirabbit IgG (1: 400;
Jackson ImmunoResearch Laboratories, West Grove, PA, USA)
and donkey Dy-light 488-labeled antimouse IgG (1: 200; Jackson
ImmunoResearch Laboratories). Negative controls were performed
substituting specific immunoglobulins with an equivalent amount
of non-specific immunoglobulins and omitting primary antibodies.
Slides were mounted with Vectashield mounting medium,
containing 4′,6′-diamino-2-phenylindole for nuclear staining
(Vector Laboratories, Burlingame, CA, USA). Examinations and
photographs were made using a fluorescence microscope (Eclipse
E600; Nikon Instruments SpA).
Statistics
Statistical analyses were conducted using GraphPad Prism version
4.00 software. Data are expressed as averages ± SD. Comparisons
were analyzed using one-way ANOVA with the Bonferroni-
corrected t-test. All experiments were performed in triple and
reproduced at least three times.
Results
In the experiments presented below Q18we used the minimum con-
centration of TMT (10μM) previously demonstrated to affect
microglial cell viability (Pompili et al., 2011). Consistently with
those previously published data, at 24 and 48h of TMT treatment
a progressive increment respective to control Q19in lactate dehydro-
genase release (indicative of necrosis and late apoptosis) wasmea-
sured in the culture medium of rat microglial primary cultures
(Fig. F11A). At earlier time points, a statistically significant increase
with respect to the untreated control in the percentage of
TUNEL-positive apoptotic cells could be measured at 8h of TMT
treatment, which then increased further at 24h (Fig. 1B).
As we already demonstrated the appearance of autophagic
vesicles in both neuronal and astrocyte cultures exposed to TMT
(Fabrizi et al., 2012, 2016), we then checked for the presence of
these vesicles also in TMT-treatedmicroglia. To that end, microglial
cells were first labeled by the fluorescent dye MDC, a compound
that marks autophagic vesicles (Vázquez & Colombo, 2009 Q20). As
shown in Fig. F22, TMT determined the appearance of many MDC-
positive structures that were not observed if this compound
was administered in combination with the autophagic inhibitor
3-methyladenine known to block autophagy at the sequestration
stage (Stroikin et al., 2004). MDC-positive vesicles were also de-
tected, as expected, after treatment with the autophagic inducer
rapamycin. In addition to late-stage autophagosomes, MDC was
also reported to label acidic endosomes and lysosomes (Munafo
& Colombo, 2001). Thus, to confirm the increased presence of
autophagosomes in TMT-treatedmicroglia, wemeasured onWest-
ern blot the amount of the lipidated form of light chain 3 (LC3-II)
(Fig. F33). In fact, LC3-II binds tightly to the autophagosomal
Figure 1. TMT cytotoxicity inmicroglial primary cultures. (A) LDH release in the culturemediumofmicroglia treatedwith TMT for 24 and 48 h. (B) Apoptotic
cells labeled by TUNEL in microglial cultures treated with TMT or staurosporine (0.5μM; positive control) at 3, 8 and 24 h. Each data point represents the av-
erage± SD of four independent experiments. ANOVA with Bonferroni’s corrected t-test. **P< 0.01, ***P< 0.001 versus untreated control. Ctrl, control; LDH,
lactic dehydrogenase; TMT, trimethyltin; TUNEL, terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling.
Autophagy block in trimethyltin-intoxicated microglia
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membrane and is considered a reliable autophagosome marker
(Kabeya et al., 2000). When treated with TMT the amount of
LC3-II increased rapidly in microglia with respect to the untreated
control (Fig. 3). This result does not necessarily indicate an
increased autophagic flux as it could be also related to an impair-
ment in the maturation of autophagic vesicles (Klionsky et al.,
2016). Thus, we analyzed LC3-II levels in microglia in the presence
of bafilomycin A1. This compound is a potent inhibitor of the
vacuolar-type H+ ATPase, which impairs lysosomal functions
blocking late stages of autophagy and consequently LC3 degrada-
tion (Boya et al., 2005; Yamamoto et al., 1998). When TMT and
bafilomycin A1 were administered in combination no further
increase in LC3-II/β-actin ratio was measured indicating that TMT
was already blocking the autophagosome maturation and conse-
quent LC3-II degradation (Fig. 3). The observed impairment in
autophagy induced by TMT persisted in up to 48h of treatment
(not shown).
As mentioned above, lithium is a modulator of autophagy
known to limit cell death and inflammatory response in many
different experimental models (Chiu et al., 2013).
When added to microglia this cation was able to reduce signifi-
cantly the TMT toxicity when used at 1–2mM (Fig. F44). Lithium
cytoprotective action against TMT was also confirmed by the
MTT test (not shown). Concentrations of lithium above 1mM are
known to inhibit the glycogen kinase synthase-3 (GSK-3) (Sarkar
et al., 2008). Other GSK-3 inhibitors, such as indirubin-3′-monoxime
or SB-216763 similarly to lithium limited TMT toxicity in microglia
(not shown).
In addition to its cytoprotective action, lithium was also able to
reduce the TMT-induced release of TNF-α. At the same time this
cation favored the production of the anti-inflammatory cytokine,
IL-10 (Fig. F55).
Lithium is also known to affect the autophagic pathway. Thus,
we decided to check if lithium pro-survival and anti-inflammatory
actions observed in our model could be related to its ability to
Figure 2. Autophagic vesicles detected by monodansylcadaverine stain-
ing. Microglial cells were left untreated or treated for 24 h with TMT alone,
TMT-positive 10mM 3-MA or 0.5μM rapamycin. Monodansylcadaverine-
positive vesicles were detected in TMT-treated samples. These vesicles were
not observed if TMTwas added in combination with the autophagy inhibitor
3-MA. Results obtained using the autophagy inducer rapamycin are shown as
positive control. Scale bar =50μm. 3-MA, 3-methyladenine; TMT, trimethyltin.
Figure 3. LC3 turnover assay in TMT-treated microglia in the presence of
a lysosomal inhibitor. (A) Western blot analysis of LC3-I/II conversion in mi-
croglia treated for 3 h with TMT alone or in combination with 100mM baf;
(B) Densitometric analysis of western blot data shown in (A). Each data
point represents the average ± SD of three independent experiments.
ANOVA with Bonferroni’s corrected t-test. ***P< 0.001 versus untreated
control; baf, bafilomycin A1; ctrl, control; LC3, light chain 3; ns, not signifi-
cant; TMT, trimethyltin.
Figure 4. Lithium protects microglial cells from trimethyltin toxicity.
Microglial cells were treated with trimethyltin alone or in combination with
lithium (0–2mM) for 24 or 48 h. Cell viability was assessed by LDH release.
Averages ± SD of four independent experiments. ANOVA with Bonferroni’s
corrected t-test. **P< 0.01, ***P< 0.001 versus untreated control. LDH,
lactic dehydrogenase.
Fabrizi C. et al.
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force the autophagic impairment induced by TMT. The analysis of
LC3-I/II conversion and p62 (also known as SQTSM1) expression
revealed that lithium was not able to revert the autophagic block
imposed by TMT at none of the concentrations used ranging from
0.5 to 2mM (Fig.F6 6A,B). In particular, this is the same range of
lithium concentrations shown before to protect microglia from
TMT toxicity and to limit its proinflammatory response (Figs 4
and 5). Figure 6 also shows the levels of expression of LC3 and
p62/SQSTM1measured in TMT-treated astrocytes that were higher
with respect to the ones obtained in microglia using the same
experimental settings.Q21
Moreover, when we checked for the expression of p62/SQSTM1
in brain slices of intoxicated rats most of the immunoreactivity was
observed in astrocytes as previously reported (Fabrizi et al., 2016),
while only few OX-42-positive microglial cells were stained (Fig.F7 7).
In control sections obtained from rats treated with saline only,
p62/SQSTM1 was hardly detectable (Fig. 7).
Discussion
Our observations of TMT-treated microglial cultures showed the
appearance of many MDC-positive vesicles and an increased
LC3-I/II conversion after exposure to this toxic compound. Both
these results are indicative of autophagosome formation. Besides,
the analysis of the autophagic flux during TMT treatment indicated
a block of autophagy at its late stages as no further increase in the
LC3-II/β-actin ratio was observed after the combined treatment of
this organotin with bafilomycin A1 (lysosomal inhibitor). The accu-
mulation of p62/SQSTM1 in TMT-treated samples is in line with the
impairment in autophagy as this protein is preferentially degraded
through this catabolic route (Bjørkøy et al., 2005). We recently de-
scribed the occurrence of an autophagic block in astrocytes intox-
icatedwith TMT (Fabrizi et al., 2016). Although an autophagic block
was observed in both astrocytes and microglia following TMT
treatment, this compound appeared to induce a much higher ac-
cumulation of LC3-II and p62/SQSTM1 in the former population
of glial cells with respect to the latter. Similarly the expression of
p62/SQSTM1 in the brain of intoxicated animals wasmostly associ-
ated to astrocytes (Fabrizi et al., 2016) while less evident in microg-
lia (present data). Although in vitro and in vivo data are in general
Figure 5. Immunomodulatory action of lithium in TMT-treatedmicroglia. Microglial cells were treated for 16 hwith TMT alone or in combinationwith lithium
(0.5, 1, 2mM) and the levels of TNF-α and IL-10 in the supernatants measured by enzyme-linked immunosorbent assay. Averages ± SD of three independent
experiments. ANOVA with Bonferroni’s corrected t-test. *P< 0.05, ***P< 0.001 versus TMT alone. IL, interleukin; TMT, trimethyltin; TNF, tumor necrosis factor.
Figure 6. Lithium is ineffective in modifying LC3 and p62/SQSTM1 accu-
mulation in TMT-treated microglia. (A) Western blot analysis of LC3-I/II con-
version and p62/SQSTM1 expression in primary microglia treated for 24 h
with TMT alone or in combination with lithium (0.5, 1 and 2mM). GAPDH
is shown as the loading reference control. Level of expression of LC3-I/II
and p62/SQSTM1 in astrocytes treated for 24 h with TMT is shown for com-
parison. (B) Densitometric analysis of Western blot data shown in (A). Aver-
ages ± SD of three independent experiments. ANOVA with Bonferroni’s
corrected t-test. *P< 0.05, **P< 0.01 versus untreated control; ns, not sig-
nificant versus TMT alone. Ctrl, control; LC3, light chain 3; TMT, trimethyltin.
Autophagy block in trimethyltin-intoxicated microglia
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difficult to compare, they are both indicative of a higher tendency
of astrocytes to accumulate autophagosomes with respect to mi-
croglia during an autophagic block, which could be related to their
high cytoplasmic/nuclear ratio.
The observed occurrence of an autophagic block during TMT
intoxication in glial cells could be possibly due to the engulfment
of autophagic vesicles with undigested materials, which cells are
unable to process further. In fact, only some microorganisms such
as bacteria (such as Pseudomonas) and phytoplankton have the
ability to degrade organotin compounds under certain conditions
(Hoch, 2001; Sampath et al., 2012). In particular, inhibition of the
autophagic flux and the p62/SQSTM1-dependent activation of
the Keap1-Nrf2 pathway has been reported to occur following ex-
posure to other toxic molecules, such as arsenic (Lau et al., 2013).
Besides, the Nrf2/p62 signaling pathway is involved in apoptosis
resistance from cadmium exposure (Son et al., 2014).
During the past few decades, an increased number of accidental
poisonings in workers acutely exposed to methyltins was reported
due to their wide industrial use (Tang et al., 2008). Currently, no
effective treatment is available for these patients.
Recently, in rodents, lithiumwas shown to ameliorate the symp-
toms of TMT intoxication. In fact, this cation can rescue seizures
and ameliorate memory deficits in TMT-intoxicated rodents,
increasing at the same time as the inhibitory phosphorylation of
GSK-3 in the hippocampusQ22 (Kim et al., 2013). Moreover, lithium en-
hances neuritogenesis ameliorating the depression-like behavior
observed in mice treated with TMT (Yoneyama et al., 2014).
During neurodegenerative diseases, neuronal loss is always ac-
companied by activation of the glia and in TMT-intoxicated brains
activatedmicroglial cells are present in affected brain areas such as
the hippocampus (Koczyk & Oderfeld-Nowak, 2000). In these
regions, the expression of proinflammatory cytokines results up-
regulated (Bruccoleri & Harry, 2000), and chronic and exaggerated
inflammatory responses by microglia can be potentially detrimen-
tal for neurons further damaging brain tissue. Thus, wide-ranging
anti-inflammatory agents with different blood–brain barrier
permeability are currently used in clinical trials for different neuro-
degenerative diseases to suppress proinflammatory cytokine
production by chronically activated microglia (for a recent review
see Perry & Holmes, 2014).
Our data are in line with previous reports showing a beneficial
effect of lithium administration in TMT-intoxicated rodents (Kim
et al., 2013; Yoneyama et al., 2014). In fact, we show that lithium
at least in vitro limits the release of a proinflammatory mediator
such as TNF-α potentiating at the same time the production of
the anti-inflammatory cytokine, IL-10.
The mechanism of action of lithium is often difficult to assess for
its multiple molecular targets, which include, among others, inosi-
tol monophosphatase and some related phosphomonoesterases,
phosphoglucomutase and GSK-3 (O’Brien & Klein, 2009). In partic-
ular, lithium can inhibit GSK-3 both indirectly and directly, compet-
ing with magnesium at its catalytic site; the Ki for GSK-3 inhibition
at typical intracellular magnesium concentrations is approximately
1.0mM (Ryves & Harwood, 2001). GSK-3 is known to promote the
inflammatory response (Martin et al., 2005) and lithium, such as
other GSK-3 inhibitors, has been demonstrated to limit the produc-
tion of inflammatory mediators in macrophages (Park et al., 2011),
dendritic cells (Rodionova et al., 2007) and microglia (Huang et al.,
2009; Yuskaitis & Jope, 2009).
Interestingly, in our microglial cultures, lithium could display its
pro-survival and immunomodulatory action without being able
to overcome the autophagic block imposed by TMT.
This appears particularly relevant because this cation, alone or in
combination with valproic acid, is considered a promising agent
for treating neurodegenerative diseases (Chiu et al., 2013) and
common features of these pathologies are protein misfolding,
aggregation and deposition, which are indicative of the possible
failure of catabolic processes in general and of autophagy in partic-
ular (Vidal et al., 2014).
In conclusion, our data indicate that lithium could potentially
maintain its beneficial effects when used for the treatment of
pathologic conditions, such as some neurodegenerative diseases,
during which an autophagic impairment is observed.
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